Indian Journal of Public Health Research & Development

Lamiaa A. Fathalla ¹, Naglaa M. Hassan ¹, Omnia K. ElGebaly ¹, Mosaad M. El Gammal ², Rasha Mahmoud Allam ³, Basma M. Elgamal ¹

Affiliations
1 Clinical Pathology department, National Cancer Institute, Cairo University, EG
2 Medical Oncology department, National Cancer Institute, Cairo University, EG
3 Biostatistics and Cancer Epidemiology Department, National Cancer Institute, Cairo University, EG

Abstract

Introduction: One of the evolving defects in acute myeloid leukemia (AML) is the BCR/ABL fusion which is the trigger of chronic myeloid leukemia (CML). Differentiating Ph +ve AML from CML in blast crisis is an ongoing challenge. In our study, we tried to differentiate between both categories and determine the prevalence of this rare entity as well as its clinical and laboratory features.

Patients and Method: We enrolled in our study 175 patients from the National Cancer Institute, Egypt; Conventional Karyotyping and qualitative RT PCR for BCR/ABL fusion proteins were done for all the patients. Positive cases were confirmed by FISH.

Results: Five/175 patients were shown to have BCR/ABL translocation with an incidence of 2.8%. Four out of the five cases were having fusion protein p210 by RT PCR, while the fifth case was having neither p210 nor p190. Most criteria of differentiation were intermingling together.

Conclusion: Further studies should be done to confirm or exclude this provisional entity. Moreover, introduction of BCR/ABL analysis in the routine may be a useful tool for introducing TKIs in these patients, which may improve the survival.

Keywords

BCR/ABL, Ph +ve AML, Qualitative RT PCR.

Full Text

     

Mai Gad ¹, Amany Abou-Bakr ², Rasha Mahmoud Allam ³, Hanan Ramdan Nassar ⁴, Maher H. Ibraheem ⁵, Soha Talima ⁶, Ghada Mohamed ⁷

Affiliations
1 Assistant Lecturer, Department of surgical Pathology, National Cancer Institute, Cairo University, EG
2 Professor, Author, National Cancer Institute, Surgical Pathology Department, Cairo University, EG
3 Lecturer, Author, Biostatistics and Cancer Epidemiology Department National Cancer Institute, Cairo University, EG
4 Professor, Medical Oncology Department, National Cancer Institute, Cairo University, EG
5 Lecturer, Surgical Oncology Department, National Cancer Institute, Cairo University, EG
6 Assistant Professor, Clinical Oncology Department (NEMROCK), Faculty of Medicine, Cairo University, EG
7 Lecturer, National Cancer Institute, Surgical Pathology Department, Cairo University, EG

Abstract

We aimed in this study to detect the correlation between PD-L1 and TILs, and their relationship with clinical outcome and survival in Egyptian patients with HGSOC.

Immunohistochemical expression of PD-L1, CD4 and CD8 was investigated in 94 HGSOC Egyptian patients. PD-L1 immunoreactivity was detected in 24% of the cases. The lack of tumor PD-L1 expression proved to be an independent predictive factor for better overall survival (OS) (p=0.01). Moreover, high stromal CD8 + TILs density had a significant impact on better disease-free survival (p=0.007). Patients who showed negative expression of PD-L1 and high intraepithelial CD8+ TILs density lived significantly longer than other patients (p=0.021).

Keywords

PD-L1, HGSOC, TILS, CD4, CD8, Survival, Egypt.

Full Text